To our knowledge, this is the first mRNA-expression analysis of all members of the HER-receptor family in addition to the ligand for HER3/4, neuregulin-1 (NRG1) in tumour and normal tissue from breast cancer patients where tissue estrogen levels have been determined in concert. Here, NRG1 is linked to breast carcinoma.